ALK(SZ:002940) news flash·2025-07-21 11:40Core Viewpoint - The company is focusing on its innovative drug business, particularly the ALK-N001 project, which is currently in Phase I clinical trials and received approval in April 2025 [1] Group 1: Innovative Drug Projects - The company has only one innovative drug project in development, ALK-N001, which is in Phase I clinical trials as of the announcement date [1] - There is growing investor interest in the ALK-N002 project, which is planned to be introduced in early 2025 and is included in the annual fundraising investment project adjustment plan [1] - Multiple candidate drugs for the ALK-N002 project are currently under screening and discussion, but specific pipeline details have not been confirmed due to commercial confidentiality [1]